DocWire News Editors

DocwireNews

Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen receptor (CAR)-T cell therapies in patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), according to research presented at the 2021 Annual Meeting and Exposition.
Lead author Samer Al Hadidi, MD, MSc, of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences in Little Rock, and collaborators examined the enrollment of Black Americans in these trials through a retrospective analysis. The seven pivotal trials included in the study evaluated the following drugs and malignancies: tisagenlecleucel for ALL (approved in 2017), axicabtagene ciloleucel for DLBCL (approved in 2017), tisagenlecleucel for DLBCL in (approved in 2018), brexucabtagene autoleucel for MCL (approved in 2020), lisocabtagene maraleucel for DLBCL in (approved in 2020), axicabtagene ciloleucel for FL in (approved in 2021), and idecabtagene vicleucel for MM (approved in 2021).
Prevalence-corrected estimates for enrollment of Blacks were calculated via the participation to prevalence ratio (PPR), defined as the percentage of Blacks among the clinical trial participants divided by the percentage of Blacks in the disease population. The report states that PPR between 0.8 and 1.2 indicates a similar representation of Black Americans between the trial and the disease populations.
Efficacy data were available for 782 of 1,051 patients enrolled in the CAR T-cell therapy trials. Black patients represented only 28 of the 782 treated patients (3.6%). Additionally, Black patients were particularly under-represented in MM studies.
Most treated patients had DLBCL (58%) or MM (16%). By specific disease, Black patients constituted only 4% of patients with DLBCL, 6% of patients with MM, and 1% of patients with other indications. The poorest PPR was in MM (0.17), a disease which the article notes is more common in Black Americans. The best PPR was in DLBCL (0.6), but still indicated suboptimal enrollment.
Dr. Hadidi concluded that “efforts should be made to enroll more Blacks in clinical trials that include novel, potentially beneficial CAR T-cell products.”

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Enrollment of Black Americans in Pivotal Chimeric Antigen Receptor-T Cell Clinical Trials

ASH Annual Meeting and Exposition 2021

Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen receptor (CAR)-T cell therapies in patients with multiple ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe